Myasthenia Gravis Market is Projected to Boost at a Moderate Growth Rate by 2032, Estimates DelveInsight | Leading Companies - DAS-MG, Catalyst, Cabaletta Bio, Janssen, Argenx, UCB Pharma, Alexion, Immunovant
25 oct. 2023 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Myasthenia Gravis Market is Projected to Boost at a Moderate Growth Rate by 2032, Estimates DelveInsight | Leading Companies - DAS-MG, Catalyst,...
What’s on Your Must-Read List? If You Work in Pharma, Add Spherix Global Insights’ Generalized Myasthenia Gravis Patient Chart Audit to that List
10 août 2023 15h15 HE
|
Spherix Global Insights
Exton, Pennsylvania, Aug. 10, 2023 (GLOBE NEWSWIRE) -- In one of the largest patient-focused studies ever conducted in gMG, Spherix’s RealWorld Dynamix™: Treatment Patterns in generalized Myasthenia...
KabaFusion Selected by UCB as a Limited Distribution Partner for RYSTIGGO® (rozanolixizumab-noli)
02 août 2023 07h00 HE
|
KabaFusion
CERRITOS, Calif. and LEXINGTON, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- KabaFusion, a nationally recognized leader in home infusion, has been selected by UCB as a limited distribution partner to...
Muscular Dystrophy Association Celebrates FDA Approval of UCB’s RYSTIGGO for the Treatment of Generalized Myasthenia Gravis
27 juin 2023 17h18 HE
|
Muscular Dystrophy Association
New York, June 27, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) approval of RYSTIGGO (rozanolixizumab-noli) for the...
Muscular Dystrophy Association Celebrates FDA Approval of argenx’s Vyvgart Hytrulo Injection for Treatment of Generalized Myasthenia Gravis
20 juin 2023 21h29 HE
|
Muscular Dystrophy Association
New York, June 20, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) approval of subcutaneous (SC) Vyvgart Hytrulo (efgartigimod...
Global Myasthenia Gravis Treatment Market Report 2023: Upsurge in the Number of Pipeline Studies for Drug Development Present Opportunities
21 mars 2023 05h33 HE
|
Research and Markets
Dublin, March 21, 2023 (GLOBE NEWSWIRE) -- The "Global Myasthenia Gravis Treatment Market (2023-2028) by Type, End-User, and Geography, Competitive Analysis, Impact of Economic Slowdown &...
Outlook on the Myasthenia Gravis Diagnosis and Treatment Global Market to 2028 - Featuring Avadel Pharmaceuticals, Bausch Health Companies, Baxter International and CSL Behring Among Others
05 janv. 2023 06h58 HE
|
Research and Markets
Dublin, Jan. 05, 2023 (GLOBE NEWSWIRE) -- The "Global Myasthenia Gravis Diagnosis and Treatment Market Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering. The global...
Catalyst Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 9, 2022
25 oct. 2022 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing,...
NMD Pharma Reports Positive Top-Line Data from a Phase I/IIa Clinical Trial of NMD670 in Patients with Myasthenia Gravis
11 oct. 2022 07h00 HE
|
NMD Pharma
NMD Pharma Reports Positive Top-Line Data from a Phase I/IIa Clinical Trial of NMD670 in Patients with Myasthenia Gravis Data provides first clinical proof of the mechanism of action of NMD Pharma’s...
NMD Pharma Reports Positive Top-Line Data from a Phase I/IIa Clinical Trial of NMD670 in Patients with Myasthenia Gravis
11 oct. 2022 01h00 HE
|
NMD Pharma
NMD Pharma Reports Positive Top-Line Data from a Phase I/IIa Clinical Trial of NMD670 in Patients with Myasthenia Gravis Data provides first clinical proof of the mechanism of action of NMD Pharma’s...